0001209191-24-000371.txt : 20240103
0001209191-24-000371.hdr.sgml : 20240103
20240103162355
ACCESSION NUMBER: 0001209191-24-000371
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231231
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ryan Jason
CENTRAL INDEX KEY: 0001585017
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39482
FILM NUMBER: 24506870
MAIL ADDRESS:
STREET 1: C/O FOUNDATION MEDICINE, INC.
STREET 2: ONE KENDALL SQUARE, SUITE B3501
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GeneDx Holdings Corp.
CENTRAL INDEX KEY: 0001818331
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 851966622
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 LUDLOW STREET
STREET 2: NORTH TOWER, 8TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 617 780 8742
MAIL ADDRESS:
STREET 1: 333 LUDLOW STREET
STREET 2: NORTH TOWER, 8TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
FORMER COMPANY:
FORMER CONFORMED NAME: Sema4 Holdings Corp.
DATE OF NAME CHANGE: 20210721
FORMER COMPANY:
FORMER CONFORMED NAME: CM Life Sciences, Inc.
DATE OF NAME CHANGE: 20200715
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-31
0
0001818331
GeneDx Holdings Corp.
WGS
0001585017
Ryan Jason
C/O GENEDX HOLDINGS CORP.
333 LUDLOW ST, NORTH TOWER
STAMFORD
CT
06902
1
1
0
0
Executive Chairman
0
Class A Common Stock
2023-12-31
4
M
0
67780
0.00
A
73614
D
Class A Common Stock
114742
I
By Jason Ryan Trust u/a dtd 11/25/2018
Restricted Stock Unit
2023-12-31
4
M
0
21780
0.00
D
Class A Common Stock
21780
0
D
Restricted Stock Unit
2023-12-31
4
M
0
46000
0.00
D
Class A Common Stock
46000
0
D
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
100% of the underlying awards shall become vested on the earlier of (A) December 31, 2023, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances.
/s/ Devin Schaffer, Attorney-in-Fact
2024-01-03